WO1997005876A1 - Use of pde inhibitors in the manufacture of a medicament for the treatment of bladder diseases - Google Patents

Use of pde inhibitors in the manufacture of a medicament for the treatment of bladder diseases Download PDF

Info

Publication number
WO1997005876A1
WO1997005876A1 PCT/EP1996/003393 EP9603393W WO9705876A1 WO 1997005876 A1 WO1997005876 A1 WO 1997005876A1 EP 9603393 W EP9603393 W EP 9603393W WO 9705876 A1 WO9705876 A1 WO 9705876A1
Authority
WO
WIPO (PCT)
Prior art keywords
pde
acid
inhibitors
treatment
inhibitor
Prior art date
Application number
PCT/EP1996/003393
Other languages
French (fr)
Other versions
WO1997005876A9 (en
Inventor
Wolf-Georg Forssmann
Michael Carsten Truss
Stefan Ückert
Christian Georg Stief
Udo Jonas
Original Assignee
Kummer Horst Dieter
Michael Carsten Truss
Ueckert Stefan
Christian Georg Stief
Forssmann Wolf Georg
Udo Jonas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kummer Horst Dieter, Michael Carsten Truss, Ueckert Stefan, Christian Georg Stief, Forssmann Wolf Georg, Udo Jonas filed Critical Kummer Horst Dieter
Priority to EP96927069A priority Critical patent/EP0843553A1/en
Priority to AU67025/96A priority patent/AU6702596A/en
Priority to JP9508103A priority patent/JP2000501698A/en
Priority to HU0104619A priority patent/HUP0104619A3/en
Priority to EA199800192A priority patent/EA199800192A1/en
Publication of WO1997005876A1 publication Critical patent/WO1997005876A1/en
Publication of WO1997005876A9 publication Critical patent/WO1997005876A9/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention pertains to the use of inhibitors of phosphodiesterase I (PDE I) for the treatment of urinary bladder diseases .
  • PDE I phosphodiesterase I
  • the physiological transmission of information for the relaxation of smooth muscle cells is effected by transmitters (messengers) of the blood (hormones) or the nerves (neurotransmitters) .
  • messengers messengers
  • neurotransmitters cause an increase in the levels of the cyclic nucleotides "cyclic adenosine monophosphate” (cAMP) and "cyclic guanosine monophosphate” (cGMP) in the smooth muscle cell, resulting in relaxation.
  • cAMP and cGMP themselves are hydrolyzed by phosphodiesterases (PDEs) .
  • Inhibitors of the PDEs in turn reduce the hydrolyzation of cAMP and cGMP, resulting in an increase of these molecules within the cell and thus in a relaxation of the smooth muscle cell.
  • This mechanism of action has been described, for instance, by CD. Nicholson, R.A. Challiss, and M. Shadid: Pulm. Pharmacol. 7 (1) (1994) , 1-17, and T.J. Torphy et al. : J. Pharmacol. Exp. Ther. 265 (3) (1993), 1213- 23.
  • PDE isoenzyme selective inhibitors An interesting target for the use of PDE isoenzyme selective inhibitors is the lower urinary tract since the pharmacological therapy of bladder dysfunctions with conventional substances is often little effective and limited by side-effects. Therefore, a well-aimed effect on the bladder muscle by inhibiting a functionally important PDE isoenzyme appears to be superior to established pharmacological treatment modalities.
  • inhibitors of phosphodiesterase I in the preparation of a drug can be used in the treatment of urinary bladder diseases.
  • Pre ⁇ ferred embodiments of the use according to the invention are related with claims 1 - 4.
  • the claim 5 deals with a method for treating urinary bladder diseases by administering an inhibitor of PDE I in a sufficient amount to a patient in need thereof. It is preferred that the formulation is given in a galenically acceptable formulation.
  • a method of identifying and classifying inhibitors of PDE I is disclosed by competitive studies using inhibitors of PDE I as competing agents.
  • PDE I is of particular importance in human bladder muscle: A well-aimed inhibition of this isoenzyme will result in relaxation of the bladder muscle even if minute doses of an inhibitor are administered, e.g., the
  • the subject matter of the invention is the use of PDE I inhibitors in the treatment of urinary bladder diseases, in particular the so-called urge symptoms, frequency, urge incon ⁇ tinence, involuntary discharge of urine, and instabilities of the bladder muscle (detrusor instability) , and the use of the inhibi ⁇ tors for the preparation of drugs useful for this purpose as well as drugs containing PDE I inhibitors for the objects mentioned.
  • Preferred inhibitors of PDE I are: vincamine, vinpocetine (ethyl apovincamin-22-oate) , and/or modified compounds of the said inhibitors having inhibiting properties for PDE I, as well as pharmacologically compatible salts thereof.
  • the pharmacologically compatible salts are obtained in a similar manner by neutralizing the bases with inorganic or organic acids.
  • inorganic acids there may be used, for example, hydrochloric acid, sulfuric acid, phosphoric acid or hydrobromic acid
  • organic acids for example, carbonic, sulfo or sulfonic acids, such as acetic acid, tartaric acid, lactic acid, propionic acid, glycolic acid, malonic acid, maleinic acid, fumaric acid, tannic acid, succinic acid, alginic acid, benzoic acid, 2-phenoxybenzoic acid, 2-acetoxybenzoic acid, cinnamic acid, mandelic acid, citric acid, malic acid, salicylic acid, 3-aminosalicylic acid, ascorbic acid, embonic acid, nicotinic acid, isonicotinic acid, oxalic acid, amino acids, methanesulfonic acid, ethanesulfonic acid, 2-
  • an effective amount of the PDE I inhibitors or salts thereof is used in addition to the usual excipients, vehicles, and additives.
  • the dosage depends on the species, body weight, age, individual condition, and type of administration.
  • Possible forms of application are oral, intravenous, intra- muscular, subcutaneous, and intraluminal (e.g. intrasvesical) formulations.
  • the latter are, in particular, solutions and formulations as used for parenteral administration as well.
  • Formulations for parenteral administration will range from 0.05 ⁇ g to 100 mg, preferably from 1 mg to 50 mg, of the compounds men ⁇ tioned per unit dose and may be present in separate unit dose forms, such as ampoules or vials.
  • solutions of the active ingredient are used, more preferably aqueous solutions, and mainly isotonic solutions, but also suspensions.
  • injection forms may be provided as a ready preparation, or they may be formulated only immediately before use by admixing the effective compound, for example, the lyophilizate, optionally with other solid carriers, with the solvent or suspension medium desired.
  • galenic prepara ⁇ tions such as tablets, coated tablets, capsules, dispersible powders, granules, aqueous or oily suspensions, syrups, liquors, or drops .
  • Solid preparations may contain inert excipients, additives and vehicles, such as calcium carbonate, calcium phosphate, sodium phosphate, lactose, starch, mannitol, alginate, gelatin, guar gum, magnesium or aluminium stearate, methylcellulose, talcum, highly dispersed silicic acids, silicone oil, higher-molecular fatty acids (such as stearic acid) , gelatin, agar-agar, or vegetable or animal fats and oils, solid high-molecular polymers (such as polyethylene glycol) ; formulations useful for oral administration may optionally contain additional flavoring and/or sweetening agents .
  • inert excipients, additives and vehicles such as calcium carbonate, calcium phosphate, sodium phosphate, lactose, starch, mannitol, alginate, gelatin, guar gum, magnesium or aluminium stearate, methylcellulose, talcum, highly dispersed silicic acids, silicone oil, higher-
  • Liquid preparations may be sterilized and/or may optionally contain additives, such as preservatives, stabilizers, wetting agents, penetration agents, emulsifiers, spreading agents, solubilizers, salts for adjusting the osmotic pressure or for buffering, and/or viscosity modifiers.
  • additives are, for instance, tartrate and citrate buffers, ethanol, complexing agents (such as ethylenediaminetetraacetic acid and its non-toxic salts) .
  • high-molecular polymers such as, for example, liquid polyethylene oxide, carboxymethylcelluloses, polyvinylpyrrolidones, dextranes, or gelatin.
  • Solid vehicles are, for instance, starch, lactose, mannitol, methylcellulose, talcum, highly dispersed silicic acids, higher-molecular fatty acids (such as stearic acid) , gelatin, agar-agar, calcium phosphate, magnesium stearate, animal and vegetable fats, solid high-molecular polymers (such as poly ⁇ ethylene glycol) .
  • Oily suspensions for parenteral or topical (in this case intra- vesicular) administrations may contain vegetable, synthetic or semisynthetic oils, such as, for instance, liquid fatty acid esters having from 8 to 22 carbon atoms in the fatty acid chains, for example, palmitic, lauric, tridecylic, margaric, stearic, arachic, myristic, behenic, pentadecylic, linolic, elaidic, brassidic, erucic or oleic acids, which may be esterified with monohydric to trihydric alcohols having from 1 to 6 carbon atoms, such as, for instance,
  • fatty acid esters are, for instance, commercially available miglyols, isopropyl myristate, isopropyl palmitate, isopropyl stearate, PEG 6-caprate, caprylates/caprates of saturated fatty alcohols, polyoxyethylene- glycerol trioleates, ethyl oleate, waxy fatty acid esters, such as synthetic duck uropygial fat, coconut oil fatty acid isopropyl ester, oleic acid oleyl ester, oleic acid decyl ester, lactic acid ethyl ester, dibutyl phthalate, adipic acid diisopropyl ester, polyol fatty acid ester, etc.
  • miglyols isopropyl myristate, isopropyl palmitate, isopropyl stearate, PEG 6-caprate, caprylates/caprates of saturated fatty alcohols, polyoxyethylene-
  • silicone oils of various viscosities or fatty alcohols such as isotridecyl alcohol, 2-octyldodecanol, cetylstearyl alcohol or oleyl alcohol, fatty acids, such as oleic acid.
  • vegetable oils such as castor oil, almond oil, olive oil, sesame oil, cottonseed oil, peanut oil or soybean oil, may be used.
  • the materials mentioned have the additional property of a spreading agent, i.e. there will be a particularly good spreading on the skin.
  • solvents such as ethanol or isopropyl alcohol, benzyl alcohol, 2-octyldodecanol, polyethyleneglycols, phthalates, adipates, propylene glycol, glycerol, dipropylene or tripropylene glycol, waxes, methyl- cellosolve, cellosolve, esters, morpholines, dioxane, dimethyl ⁇ sulfoxide, dimethylformamide, tetrahydrofurane, cyclohexanone, etc.
  • alcohols such as ethanol or isopropyl alcohol
  • benzyl alcohol 2-octyldodecanol
  • polyethyleneglycols phthalates
  • adipates propylene glycol
  • glycerol propylene glycol
  • dipropylene or tripropylene glycol waxes
  • methyl- cellosolve cellosolve
  • esters morpholines
  • dioxane dimethyl ⁇
  • cellulose ethers which can dissolve or swell both in water and in organic solvents and will form a kind of film after drying, such as hydroxypropyl ⁇ cellulose, methylcellulose, ethylcellulose, or soluble starches.
  • Mixed gelling and film-forming agents are also possible.
  • ionic macromolecules such as sodium carboxymethylcellulose, polyacrylic acid, polymethacrylic acid, and salts thereof, sodium amylopectine semiglycolate, alginic acid or propylene glycol sodium salt, gum arabic, xanthan gum, guar gum or carrageen.
  • glycerol paraffins having different viscosities
  • triethanolamine triethanolamine
  • collagen allantoin
  • novantisolic acid perfume oils
  • surfactants such as, for example, sodium lauryl sulfate, fatty alcohol ether sulfates, disodium N-lauryl ?-iminodipropionate, polyoxyethylated castor oil, or sorbitan monooleate, sorbitan monostearate, cetyl alcohol, lecithin, glycerol monostearate, polyoxyethylene stearate, alkylphenol polyglycol ether, cetyltrimethylammonium chloride, or monoalkyl/ dialkyl polyglycol ether ortho-phosphoric acid monoethanolamine salts .
  • surfactants such as, for example, sodium lauryl sulfate, fatty alcohol ether sulfates, disodium N-lauryl ?-iminodipropionate, polyoxyethylated castor oil, or sorbitan monooleate, sorbitan monostearate, cetyl alcohol, lecithin, glycerol
  • Stabilizers such as montmorillonites or colloidal silicic acids, for the stabilization of emulsions or for preventing decomposition of active substances, such as antioxidants, for example, toco ⁇ pherols or butylhydroxyanisol, or preservatives, such as p-hydroxybenzoic acid ester, may also be required for the pre ⁇ paration of the formulations desired.
  • active substances such as antioxidants, for example, toco ⁇ pherols or butylhydroxyanisol
  • preservatives such as p-hydroxybenzoic acid ester
  • mtravesicular formulations preferably contain highly compatible organic solvents, such as ethanol, methylpyrrolidone, polyethylene glycol, oleyl alcohol, octanol, linolic acid, triacetin, propylene glycol, glycerol, solketal, or dimethylsulfoxide.
  • highly compatible organic solvents such as ethanol, methylpyrrolidone, polyethylene glycol, oleyl alcohol, octanol, linolic acid, triacetin, propylene glycol, glycerol, solketal, or dimethylsulfoxide.
  • preparations filling and sealing of the preparations is done under the usual antimicrobial and aseptic conditions.
  • preparations are preferably packed in separate unit doses for easy handling, if required for stability reasons, as with parenteral forms, also by separately packing the active ingredients or their combinations as lyophilizates, optionally with solid carriers, and the solvents required etc.
  • Human urinary bladder muscles freshly collected in the course of an operation is cut into small strips (about 3 3 x 6 mm) .
  • the latter are then installed in an organ bath containing a nutrient solution ensuring survival of the organic strips.
  • a measuring element By coupling the organic strips to a measuring element, length and force changes of the organic strip can be recorded, and thus actions of compounds added to the organ bath nutrient solution can be examined through the length and force changes (increase or decrease) of the organic strip.
  • the organic strips are contracted with an appropriate standard compound (e.g., carbachol) .
  • an inhibitor of phosphodiesterase I is now added in incremental dosage (10 '9 , 10 "8 , IO "7 etc. mol/l) to the organ bath solution, and the relaxation triggered thereby is measured.
  • the results obtained are essentially applicable to the whole organism since human tissue had been used and the metabolic processes studied proceed faster in the whole organism and thus the compounds will act even more pronounced.
  • FIGS 1 to 6 illustrate the results of these organ bath experiments.
  • Figure 1 shows the relaxing effect of cumulatively increasing concentrations of papaverine, an non-specific phosphodiesterase inhibitor, on human detrusor strips precontracted with 1 ⁇ M carbachol .
  • the curve shows the average values of measurements each performed on 12 detrusor strips. This no drug, because of its severe side-effects due to interaction with all PDEs.
  • Figure 2 shows the relaxing effect of cumulatively increasing concentrations of vinpocetine, an inhibitor of PDE I, on human detrusor strips precontracted with 1 ⁇ M carbachol .
  • the curve shows the average values of measurements each performed on 12 detrusor strips .
  • Figure 3 shows the relaxing effect of cumulatively increasing concentrations of milrinone, an inhibitor of PDE III, on human detrusor strips precontracted with 1 ⁇ M carbachol .
  • the curve shows the average values of measurements each performed on 10 detrusor strips .
  • Figure 4 shows the relaxing effect of cumulatively increasing concentrations of rolipram, an inhibitor of PDE IV, on human detrusor strips precontracted with 1 ⁇ M carbachol .
  • the curve shows the average values of measurements each performed on 8 detrusor strips .
  • Figure 5 shows the relaxing effect of cumulatively increasing concentrations of zaprinast, an inhibitor of PDE V, on human detrusor strips precontracted with 1 ⁇ M carbachol.
  • the curve shows the average values of measurements each performed on 10 detrusor strips.
  • Figure 6 shows the relaxing effect of cumulatively increasing concentrations of dipyridamole, an inhibitor of PDE V, on human detrusor strips precontracted with 1 ⁇ M carbachol.
  • the curve shows the average values of measurements each performed on 10 detrusor strips.
  • Inhibitors of PDE II have not been known to date and therefore could not be tested.
  • Fresh tissue obtained during an operation is homogenized and then ultracentrifuged. Next, the supernatant is filtered, pipetted off and chromatographed. The determination of PDE isoenzymes is performed as described in M. Truss et al. : Urology 45(5) : 893-901, 1995. The determination of the amount of radioactivity permits to calculate the enzyme activity in pmol/ ml/min. A plot of the activity curve allows to identify fractions in which the phospho ⁇ diesterase activity is particularly high. The phosphodiesterase activity of each of the peaks exhibits a different composition with respect to the activity of the different substrates.
  • This special composition of the phosphodiesterase activity allows for the assignment to a phosphodiesterase isoenzyme (PDE) .
  • a substance is considered as PDE inhibitor if the concentration thereof which is necessary for inhibiting 50% of the substrate hydrolysis (IC-- n ) is at least 20 times lower in the respective peak fraction con ⁇ taining the correspoonding phosphodiesterase isoenzyme than in other peak fractions.
  • enzyme preparations are again carried out, as described above. Now, however, the compound to be tested is added prior to the incubation of the enzyme mixtures according to peak fractions. Then, renewed determination and plotting of the enzyme activity allows to identify a substance as being an inhibitor of the phosphodiesterase isoenzyme according to the above-mentioned definition.

Abstract

The present invention pertains to the use of inhibitors of phosphodiesterase I for the treatment of urinary bladder diseases, in particular the use of vincamine, vinpocetine (ethyl apovincamin-22-oate), and/or modified compounds of the said inhibitors having inhibiting properties for PDE I, as well as pharmacologically compatible salts thereof, in local and systemic administration.

Description

USE OF PDE INHIBITORS IN THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF BLADDER DISEASES
The present invention pertains to the use of inhibitors of phosphodiesterase I (PDE I) for the treatment of urinary bladder diseases .
The physiological transmission of information for the relaxation of smooth muscle cells is effected by transmitters (messengers) of the blood (hormones) or the nerves (neurotransmitters) . These messengers and neurotransmitters cause an increase in the levels of the cyclic nucleotides "cyclic adenosine monophosphate" (cAMP) and "cyclic guanosine monophosphate" (cGMP) in the smooth muscle cell, resulting in relaxation. cAMP and cGMP themselves are hydrolyzed by phosphodiesterases (PDEs) . Inhibitors of the PDEs in turn reduce the hydrolyzation of cAMP and cGMP, resulting in an increase of these molecules within the cell and thus in a relaxation of the smooth muscle cell. This mechanism of action has been described, for instance, by CD. Nicholson, R.A. Challiss, and M. Shadid: Pulm. Pharmacol. 7 (1) (1994) , 1-17, and T.J. Torphy et al. : J. Pharmacol. Exp. Ther. 265 (3) (1993), 1213- 23.
From these publications as well as from W.J. Thompson: Pharmacol. Ther. 51 (1991) , 13-33, and J. Beavo in: J. Beavo and M.D. Housley (eds.) : Cyclic nucleotide phosphodiesterases : Structure, regula¬ tion and drug action, Chichester, New YorkBrisbane-Toronto-Singa- pore, Wiley, 1990: 3-15; there is further known the distinction of a number of isoenzymes of PDEs is distinguished between five different PDEs (I - V) which are differently distributed in the individual organs and organ systems and have di ferent activities according to their distribution. In the publications mentioned, there is also discussed the occurrence of the different isoenzymes in various tissues.
An interesting target for the use of PDE isoenzyme selective inhibitors is the lower urinary tract since the pharmacological therapy of bladder dysfunctions with conventional substances is often little effective and limited by side-effects. Therefore, a well-aimed effect on the bladder muscle by inhibiting a functionally important PDE isoenzyme appears to be superior to established pharmacological treatment modalities.
According to the invention it has surprisingly been found that inhibitors of phosphodiesterase I in the preparation of a drug can be used in the treatment of urinary bladder diseases. Pre¬ ferred embodiments of the use according to the invention are related with claims 1 - 4. The claim 5 deals with a method for treating urinary bladder diseases by administering an inhibitor of PDE I in a sufficient amount to a patient in need thereof. It is preferred that the formulation is given in a galenically acceptable formulation.
According to the invention a method of identifying and classifying inhibitors of PDE I is disclosed by competitive studies using inhibitors of PDE I as competing agents.
Surprisingly, it has now been found that PDE I is of particular importance in human bladder muscle: A well-aimed inhibition of this isoenzyme will result in relaxation of the bladder muscle even if minute doses of an inhibitor are administered, e.g., the
_5 PDE I inhibitor vinpocetine in a dosage of 10 mol/l (figure 2) , with no appreciable effects to other organs, in particular to vessels. Therefore, there is an excellent efficacy and potency in the treatment of urinary bladder diseases. Therefore, the subject matter of the invention is the use of PDE I inhibitors in the treatment of urinary bladder diseases, in particular the so-called urge symptoms, frequency, urge incon¬ tinence, involuntary discharge of urine, and instabilities of the bladder muscle (detrusor instability) , and the use of the inhibi¬ tors for the preparation of drugs useful for this purpose as well as drugs containing PDE I inhibitors for the objects mentioned.
Preferred inhibitors of PDE I are: vincamine, vinpocetine (ethyl apovincamin-22-oate) , and/or modified compounds of the said inhibitors having inhibiting properties for PDE I, as well as pharmacologically compatible salts thereof.
The pharmacologically compatible salts are obtained in a similar manner by neutralizing the bases with inorganic or organic acids. As inorganic acids, there may be used, for example, hydrochloric acid, sulfuric acid, phosphoric acid or hydrobromic acid, and as the organic acids, for example, carbonic, sulfo or sulfonic acids, such as acetic acid, tartaric acid, lactic acid, propionic acid, glycolic acid, malonic acid, maleinic acid, fumaric acid, tannic acid, succinic acid, alginic acid, benzoic acid, 2-phenoxybenzoic acid, 2-acetoxybenzoic acid, cinnamic acid, mandelic acid, citric acid, malic acid, salicylic acid, 3-aminosalicylic acid, ascorbic acid, embonic acid, nicotinic acid, isonicotinic acid, oxalic acid, amino acids, methanesulfonic acid, ethanesulfonic acid, 2- hydroxyethanesulfonic acid, ethane-1, 2-disulfonic acid, benzene¬ sulfonic acid, 4-methylbenzenesulfonic acid, or naphthalene-2- sulfonic acid.
In the preparation of the drugs for the treatment of the diseases mentioned, an effective amount of the PDE I inhibitors or salts thereof is used in addition to the usual excipients, vehicles, and additives. The dosage depends on the species, body weight, age, individual condition, and type of administration.
Possible forms of application are oral, intravenous, intra- muscular, subcutaneous, and intraluminal (e.g. intrasvesical) formulations. The latter are, in particular, solutions and formulations as used for parenteral administration as well.
Formulations for parenteral administration will range from 0.05 μg to 100 mg, preferably from 1 mg to 50 mg, of the compounds men¬ tioned per unit dose and may be present in separate unit dose forms, such as ampoules or vials. Preferably, solutions of the active ingredient are used, more preferably aqueous solutions, and mainly isotonic solutions, but also suspensions. These injection forms may be provided as a ready preparation, or they may be formulated only immediately before use by admixing the effective compound, for example, the lyophilizate, optionally with other solid carriers, with the solvent or suspension medium desired.
For oral administration, there are used the usual galenic prepara¬ tions, such as tablets, coated tablets, capsules, dispersible powders, granules, aqueous or oily suspensions, syrups, liquors, or drops .
Solid preparations may contain inert excipients, additives and vehicles, such as calcium carbonate, calcium phosphate, sodium phosphate, lactose, starch, mannitol, alginate, gelatin, guar gum, magnesium or aluminium stearate, methylcellulose, talcum, highly dispersed silicic acids, silicone oil, higher-molecular fatty acids (such as stearic acid) , gelatin, agar-agar, or vegetable or animal fats and oils, solid high-molecular polymers (such as polyethylene glycol) ; formulations useful for oral administration may optionally contain additional flavoring and/or sweetening agents .
Liquid preparations may be sterilized and/or may optionally contain additives, such as preservatives, stabilizers, wetting agents, penetration agents, emulsifiers, spreading agents, solubilizers, salts for adjusting the osmotic pressure or for buffering, and/or viscosity modifiers. Such additives are, for instance, tartrate and citrate buffers, ethanol, complexing agents (such as ethylenediaminetetraacetic acid and its non-toxic salts) .
For adjusting the viscosity, there may be used high-molecular polymers, such as, for example, liquid polyethylene oxide, carboxymethylcelluloses, polyvinylpyrrolidones, dextranes, or gelatin. Solid vehicles are, for instance, starch, lactose, mannitol, methylcellulose, talcum, highly dispersed silicic acids, higher-molecular fatty acids (such as stearic acid) , gelatin, agar-agar, calcium phosphate, magnesium stearate, animal and vegetable fats, solid high-molecular polymers (such as poly¬ ethylene glycol) .
Oily suspensions for parenteral or topical (in this case intra- vesicular) administrations may contain vegetable, synthetic or semisynthetic oils, such as, for instance, liquid fatty acid esters having from 8 to 22 carbon atoms in the fatty acid chains, for example, palmitic, lauric, tridecylic, margaric, stearic, arachic, myristic, behenic, pentadecylic, linolic, elaidic, brassidic, erucic or oleic acids, which may be esterified with monohydric to trihydric alcohols having from 1 to 6 carbon atoms, such as, for instance,
methanol, ethanol, propanol, butanol, pentanol, or isomers thereof, glycol, or glycerol. Such fatty acid esters are, for instance, commercially available miglyols, isopropyl myristate, isopropyl palmitate, isopropyl stearate, PEG 6-caprate, caprylates/caprates of saturated fatty alcohols, polyoxyethylene- glycerol trioleates, ethyl oleate, waxy fatty acid esters, such as synthetic duck uropygial fat, coconut oil fatty acid isopropyl ester, oleic acid oleyl ester, oleic acid decyl ester, lactic acid ethyl ester, dibutyl phthalate, adipic acid diisopropyl ester, polyol fatty acid ester, etc. Also useful are silicone oils of various viscosities or fatty alcohols, such as isotridecyl alcohol, 2-octyldodecanol, cetylstearyl alcohol or oleyl alcohol, fatty acids, such as oleic acid. Further, vegetable oils, such as castor oil, almond oil, olive oil, sesame oil, cottonseed oil, peanut oil or soybean oil, may be used. The materials mentioned have the additional property of a spreading agent, i.e. there will be a particularly good spreading on the skin.
As solvents, gelling agents and solubilizers, there may be used water or water-miscible solvents, for example alcohols, such as ethanol or isopropyl alcohol, benzyl alcohol, 2-octyldodecanol, polyethyleneglycols, phthalates, adipates, propylene glycol, glycerol, dipropylene or tripropylene glycol, waxes, methyl- cellosolve, cellosolve, esters, morpholines, dioxane, dimethyl¬ sulfoxide, dimethylformamide, tetrahydrofurane, cyclohexanone, etc.
As film-forming agents, there may be used cellulose ethers which can dissolve or swell both in water and in organic solvents and will form a kind of film after drying, such as hydroxypropyl¬ cellulose, methylcellulose, ethylcellulose, or soluble starches. Mixed gelling and film-forming agents are also possible. In this case, there are chiefly used ionic macromolecules, such as sodium carboxymethylcellulose, polyacrylic acid, polymethacrylic acid, and salts thereof, sodium amylopectine semiglycolate, alginic acid or propylene glycol sodium salt, gum arabic, xanthan gum, guar gum or carrageen.
As additional formulation aids, there may be used: glycerol, paraffins having different viscosities, triethanolamine, collagen, allantoin, novantisolic acid, perfume oils.
The use of surfactants, emulsifiers or wetting agents may also be required for the formulation, such as, for example, sodium lauryl sulfate, fatty alcohol ether sulfates, disodium N-lauryl ?-iminodipropionate, polyoxyethylated castor oil, or sorbitan monooleate, sorbitan monostearate, cetyl alcohol, lecithin, glycerol monostearate, polyoxyethylene stearate, alkylphenol polyglycol ether, cetyltrimethylammonium chloride, or monoalkyl/ dialkyl polyglycol ether ortho-phosphoric acid monoethanolamine salts .
Stabilizers, such as montmorillonites or colloidal silicic acids, for the stabilization of emulsions or for preventing decomposition of active substances, such as antioxidants, for example, toco¬ pherols or butylhydroxyanisol, or preservatives, such as p-hydroxybenzoic acid ester, may also be required for the pre¬ paration of the formulations desired.
For promoting penetration, mtravesicular formulations preferably contain highly compatible organic solvents, such as ethanol, methylpyrrolidone, polyethylene glycol, oleyl alcohol, octanol, linolic acid, triacetin, propylene glycol, glycerol, solketal, or dimethylsulfoxide.
The preparation, filling and sealing of the preparations is done under the usual antimicrobial and aseptic conditions. For topical or transdermal application as well, the preparations are preferably packed in separate unit doses for easy handling, if required for stability reasons, as with parenteral forms, also by separately packing the active ingredients or their combinations as lyophilizates, optionally with solid carriers, and the solvents required etc.
Example 1 - Injection
Fifty milligrams of vinpocetine are dissolved m distilled water together with 750 mg of NaCl, the pH is adjusted to 3.7 with 1 N HCl, distilled water is added to give a total of 100 ml, and the solution is packed m 0.5 ml ampoules.
Example 2 - Solution for Topical Administration
From 500 mg of vinpocetine, 2 ml of isopropyl myristate and 10 ml of ethanol, a solution for topical administration is prepared and packed m unit doses of 2 ml each. The efficacy and potency of the drugs according to the teaching of the invention is demonstrated by the following pharmacological studies :
Human urinary bladder muscles freshly collected in the course of an operation is cut into small strips (about 3 3 x 6 mm) . The latter are then installed in an organ bath containing a nutrient solution ensuring survival of the organic strips. By coupling the organic strips to a measuring element, length and force changes of the organic strip can be recorded, and thus actions of compounds added to the organ bath nutrient solution can be examined through the length and force changes (increase or decrease) of the organic strip. At the beginning of the experi¬ ment, the organic strips are contracted with an appropriate standard compound (e.g., carbachol) . After the contraction of the organic strips is completed, an inhibitor of phosphodiesterase I is now added in incremental dosage (10'9, 10"8, IO"7 etc. mol/l) to the organ bath solution, and the relaxation triggered thereby is measured. The results obtained are essentially applicable to the whole organism since human tissue had been used and the metabolic processes studied proceed faster in the whole organism and thus the compounds will act even more pronounced.
Figures 1 to 6 illustrate the results of these organ bath experiments.
Figure 1 shows the relaxing effect of cumulatively increasing concentrations of papaverine, an non-specific phosphodiesterase inhibitor, on human detrusor strips precontracted with 1 μM carbachol . The curve shows the average values of measurements each performed on 12 detrusor strips. This no drug, because of its severe side-effects due to interaction with all PDEs.
Figure 2 shows the relaxing effect of cumulatively increasing concentrations of vinpocetine, an inhibitor of PDE I, on human detrusor strips precontracted with 1 μM carbachol . The curve shows the average values of measurements each performed on 12 detrusor strips .
Figure 3 shows the relaxing effect of cumulatively increasing concentrations of milrinone, an inhibitor of PDE III, on human detrusor strips precontracted with 1 μM carbachol . The curve shows the average values of measurements each performed on 10 detrusor strips .
Figure 4 shows the relaxing effect of cumulatively increasing concentrations of rolipram, an inhibitor of PDE IV, on human detrusor strips precontracted with 1 μM carbachol . The curve shows the average values of measurements each performed on 8 detrusor strips .
Figure 5 shows the relaxing effect of cumulatively increasing concentrations of zaprinast, an inhibitor of PDE V, on human detrusor strips precontracted with 1 μM carbachol. The curve shows the average values of measurements each performed on 10 detrusor strips.
Figure 6 shows the relaxing effect of cumulatively increasing concentrations of dipyridamole, an inhibitor of PDE V, on human detrusor strips precontracted with 1 μM carbachol. The curve shows the average values of measurements each performed on 10 detrusor strips. Inhibitors of PDE II have not been known to date and therefore could not be tested.
The proof as to whether a compound is suitable for the purpose according to the invention, i.e. is an inhibitor of PDE I, is furnished by known methods, such as described by Galwan et al . , Arch. Pharmacol. 1990, 342, 221-227; or Nicholson, Br. J. Pharmacol. 1989, 79, 889-897; for example, according to the following general procedure:
Fresh tissue obtained during an operation is homogenized and then ultracentrifuged. Next, the supernatant is filtered, pipetted off and chromatographed. The determination of PDE isoenzymes is performed as described in M. Truss et al. : Urology 45(5) : 893-901, 1995. The determination of the amount of radioactivity permits to calculate the enzyme activity in pmol/ ml/min. A plot of the activity curve allows to identify fractions in which the phospho¬ diesterase activity is particularly high. The phosphodiesterase activity of each of the peaks exhibits a different composition with respect to the activity of the different substrates. This special composition of the phosphodiesterase activity allows for the assignment to a phosphodiesterase isoenzyme (PDE) . A substance is considered as PDE inhibitor if the concentration thereof which is necessary for inhibiting 50% of the substrate hydrolysis (IC--n) is at least 20 times lower in the respective peak fraction con¬ taining the correspoonding phosphodiesterase isoenzyme than in other peak fractions. For this purpose, enzyme preparations are again carried out, as described above. Now, however, the compound to be tested is added prior to the incubation of the enzyme mixtures according to peak fractions. Then, renewed determination and plotting of the enzyme activity allows to identify a substance as being an inhibitor of the phosphodiesterase isoenzyme according to the above-mentioned definition.

Claims

C L A I M S :
1. Use of inhibitors of phosphodiesterase I in the preparation of a drug for the treatment of urinary bladder diseases.
2. Use according to claim 1 for the treatment of urge symptoms, frequency, urge incontinence, involuntary discharge of urine, and instabilities of the bladder muscle (detrusor instabilities) .
3. Use according to claim 1 wherein the inhibitor of phospho¬ diesterase I is vincamine, vinpocetine (ethyl apovincamin-22-oate) , and/or modified compounds of the said inhibitors having inhibiting properties for PDE I, as well as pharmacologically compatible salts thereof for treatment according to claim 1.
4. The use according to any of claims 1 through 2 in local or systemic administration.
5. A method for treating urinary bladder diseases by administer¬ ing to a patient in need an inhibitor of PDE I in a sufficient amou t, optionally in a galenically acceptable formulation.
6. A method of identifying and classifying inhibitors of PDE I by competitive studies using as competing agents of the PDE I the following compounds vincamine, vinpocetine (ethyl apovincamin-22-oate) , and/or modified compounds of the said inhibitors having inhibiting properties for PDE I, as well as pharmacologically compatible salts thereof.
PCT/EP1996/003393 1995-08-08 1996-08-01 Use of pde inhibitors in the manufacture of a medicament for the treatment of bladder diseases WO1997005876A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP96927069A EP0843553A1 (en) 1995-08-08 1996-08-01 Use of pde inhibitors in the manufacture of a medicament for the treatment of bladder diseases
AU67025/96A AU6702596A (en) 1995-08-08 1996-08-01 Use of pde inhibitors in the manufacture of a medicament for the treatment of bladder diseases
JP9508103A JP2000501698A (en) 1995-08-08 1996-08-01 Use of PDE inhibitors in the treatment of urinary bladder disease
HU0104619A HUP0104619A3 (en) 1995-08-08 1996-08-01 Use of pde inhibitors in the manufacture of a medicament for the treatment of bladder diseases
EA199800192A EA199800192A1 (en) 1995-08-08 1996-08-01 APPLICATION OF PHOSPHODYSTERASE INHIBITORS (PDE) IN THE MANUFACTURE OF MEDICINES FOR THE TREATMENT OF URINARY BUBBLE DISEASES

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19529102.6 1995-08-08
DE19529102A DE19529102A1 (en) 1995-08-08 1995-08-08 Use of PDE inhibitors in the treatment of bladder disorders

Publications (2)

Publication Number Publication Date
WO1997005876A1 true WO1997005876A1 (en) 1997-02-20
WO1997005876A9 WO1997005876A9 (en) 1997-04-03

Family

ID=7768971

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1996/003393 WO1997005876A1 (en) 1995-08-08 1996-08-01 Use of pde inhibitors in the manufacture of a medicament for the treatment of bladder diseases

Country Status (9)

Country Link
EP (1) EP0843553A1 (en)
JP (1) JP2000501698A (en)
AU (1) AU6702596A (en)
CA (1) CA2228314A1 (en)
DE (1) DE19529102A1 (en)
EA (1) EA199800192A1 (en)
HU (1) HUP0104619A3 (en)
WO (1) WO1997005876A1 (en)
ZA (1) ZA966698B (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001017480A2 (en) * 1999-09-09 2001-03-15 Androsolutions, Inc. Methods and compositions for preventing and treating urinary tract disorders
US6812239B2 (en) * 1999-02-05 2004-11-02 Albert Einstein College Of Medicine Of Yeshiva University Method of identification of inhibitors of PDE1C and methods of treatment of diabetes
US8106061B2 (en) * 1997-07-09 2012-01-31 Uropep Biotech Gbr Use of phosphodiesterase inhibitors in the treatment of prostatic diseases

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0546547A1 (en) * 1991-12-10 1993-06-16 Hoechst Japan Limited Pharmaceutical composition for the improvement of dysuria
EP0722944A1 (en) * 1995-01-19 1996-07-24 Bayer Ag 2-9-Disubstituted Purin-6-ones

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0546547A1 (en) * 1991-12-10 1993-06-16 Hoechst Japan Limited Pharmaceutical composition for the improvement of dysuria
EP0722944A1 (en) * 1995-01-19 1996-07-24 Bayer Ag 2-9-Disubstituted Purin-6-ones

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
TRUSS ET AL: "Cyclic nucleotide phosphodiesterase (PDE) isoenzymes in the human detrusor smooth muscle", UROL RES, vol. 24, 1996, pages 129 - 34, XP000609239 *
TRUSS ET AL: "Effects of various phosphodiesterase-inhibitors, Forskolin, and sodium nitroprusside on porcine detrusor smooth muscle tonic response to muscarinergic stimulation and cyclic nucleotide levels in vitro", NEUROUROLOGY AND URODYNAMICS, vol. 15, January 1996 (1996-01-01), pages 59 - 70, XP000609243 *
TRUSS ET AL: "Porcine cyclic nucleotide phosphodiesterase isoenzymes: characterization and functional effects of various phosphodiesterase inhibitors in vitro", UROLOGY, vol. 45, no. 5, May 1995 (1995-05-01), pages 893 - 901, XP000609244 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8106061B2 (en) * 1997-07-09 2012-01-31 Uropep Biotech Gbr Use of phosphodiesterase inhibitors in the treatment of prostatic diseases
US6812239B2 (en) * 1999-02-05 2004-11-02 Albert Einstein College Of Medicine Of Yeshiva University Method of identification of inhibitors of PDE1C and methods of treatment of diabetes
WO2001017480A2 (en) * 1999-09-09 2001-03-15 Androsolutions, Inc. Methods and compositions for preventing and treating urinary tract disorders
WO2001017480A3 (en) * 1999-09-09 2001-11-01 Androsolutions Inc Methods and compositions for preventing and treating urinary tract disorders

Also Published As

Publication number Publication date
EA199800192A1 (en) 1999-06-24
DE19529102A1 (en) 1997-02-13
HUP0104619A2 (en) 2002-04-29
JP2000501698A (en) 2000-02-15
HUP0104619A3 (en) 2002-06-28
ZA966698B (en) 1998-02-09
EP0843553A1 (en) 1998-05-27
AU6702596A (en) 1997-03-05
CA2228314A1 (en) 1997-02-20

Similar Documents

Publication Publication Date Title
US6083483A (en) Inhibitors of phosphodiesterase IV for x-ray imaging
US6391869B1 (en) Compositions and methods for the treatment of anorectal disorders
US6395736B1 (en) Compositions and methods for the treatment of anorectal disorders
US8551967B2 (en) Formulations with anti-tumour action
US5891904A (en) Use of inhibitors of phosphodiesterase IV
EP1477166A1 (en) The use of riluzol combined with excipients and additives for the treatment of disorders characterised by hyperproliferation of keratinocytes, in particular neurodermitis and psoriasis
PT2035006E (en) Use of allopurinol for the treatment of palmar plantar erythrodysesthesia
ES2312588T3 (en) REGULATION OF THE PANCREATIC JUICE SECRETION UNDERSTANDING A LPA RECEIVER REGULATION AGENT.
CA2295616C (en) Use of phosphodiesterase inhibitors in the treatment of prostatic diseases
US8791124B2 (en) Use of phosphordiesterase inhibitors in the treatment of prostatic diseases
US20230414617A1 (en) Pharmaceutical composition comprising acid-base neutralization combination and application thereof
WO2008129000A1 (en) Pyridopyrimidine derivatives and use thereof in the treatment of itch and itch related disorders
US11141421B2 (en) Antitumor agent for biliary tract cancer and method for treating biliary tract cancer
US6008222A (en) Method for oral administration of buspirone and nefazodone
EP0843553A1 (en) Use of pde inhibitors in the manufacture of a medicament for the treatment of bladder diseases
WO1997005876A9 (en) Use of pde inhibitors in the manufacture of a medicament for the treatment of bladder diseases
DE19540642A1 (en) Use of phosphodiesterase I, IV and V inhibitors
JPH11279080A (en) Composition for decreasing cicatrix
US7378401B2 (en) Use of Fosfluridine Tidoxil (FT) for the treatment of intraepithelial proliferative diseases
DE4230755A1 (en) Phosphodiesterase IV inhibitors for kidney and ureter disease treatment - with eg (4-(3-(cyclopentyl oxy) 4-methoxyphenyl-2-pyrrolidinone) being specific for kidney and ureter tissue relaxation
CN1205634A (en) Use of PDE inhibitors in manufacture of medicament for treatment of bladder diseases
CN113577059B (en) Active medicine for treating infantile asthma
CA2174240A1 (en) Use of peniclorin for the treatment of posttherapeutic neuralgia
ZA200104778B (en) Compositions and methods for the treatment of anorectal disorders.
AU2004212586A1 (en) Compositions and methods for the treatment of anorectal disorders

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 96197169.X

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AU BB BG BR CA CN CU CZ EE GE HU IL IS JP KP KR LK LR LT LV MG MK MN MX NO NZ PL RO SG SI SK TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/6-6/6,DRAWINGS,REPLACED BY NEW PAGES BEARING THE SAME NUMBER;DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2228314

Country of ref document: CA

Ref document number: 2228314

Country of ref document: CA

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 1997 508103

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1996927069

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 199800192

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 1996927069

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1996927069

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1996927069

Country of ref document: EP